We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Pfizer/BioNTech Could File for Full Vaccine Approval in April, with Trial Showing High Efficacy After Six Months
Pfizer/BioNTech Could File for Full Vaccine Approval in April, with Trial Showing High Efficacy After Six Months
Pfizer and BioNTech have accrued the data necessary to submit a biologics license application (BLA) for their COVID-19 vaccine and are seeking full approval as soon as this month, following a recent analysis from their phase 3 trial showing the vaccine held 91.3 percent efficacy up to six months after the second dose.